Deciphering antiviral mechanisms during a pandemic
At the onset of the COVID-19 pandemic, many research groups pivoted their focus to the development and understanding of drugs that could be used to combat the deadly virus SARS-CoV-2. When Calvin Gordon joined at the , his initial goal was to study the inhibition of , enzymes that are responsible for replication in viruses like Ebola, influenza and severe acute respiratory syndrome, or SARS.
Gordon first discovered his passion for research during the last two years of undergraduate study at of Calgary, Alberta. Before entering his first year of graduate study, Gordon was encouraged by a friend and fellow U of A graduate student to seek professor G枚tte due to their aligning research interests. Gordon found the lab to be a perfect fit.
In March of 2020, as a consequence of the pandemic, Gordon’s focus shifted to understanding the mechanisms behind broad-spectrum antivirals such as remdesivir and molnupiravir. His research led to the publication of a in the Journal of Biological Chemistry detailing the mechanism of molnupiravir’s interaction with SARS-Cov-2 on a molecular level.
Like many scientists performing essential research at the height of the pandemic, Gordon found the experience to be stressful yet humbling.
“It was a weird and mentally taxing experience for sure,” he said. “We were fortunate, being able to go into the lab and maintain a routine with our research — not many people could do that.”
Gordon is working toward his Ph.D. in medical microbiology and immunology at the University of Alberta and enjoying every minute. “My favorite part is being at the bench, running assays,” he said. “I pinch myself most days because I get to come into the lab and work with incredible people.”
When asked about his future, Gordon said that he hopes to recognize where the opportunities are and make the most of them.
How molnupiravir works against COVID-19
Molnupiravir is a broad-spectrum antiviral drug that first was approved in the U.K. in November 2021 and later won emergency approval in the U.S. to treat SARS-CoV-2 viral infection in adults.
Early in the pandemic, Calvin Gordon and others in Matthias G枚tte’s lab became interested in understanding how antivirals like molnupiravir work against SARS-CoV-2. The lab’s previous experience researching coronaviruses such as , or MERS, allowed them to begin evaluating drugs designed to combat SARS-CoV-2.
The researchers found that molnupiravir interferes with the viral replication cycle. Here, the drug can serve as a substrate for , which are enzymes that are responsible for replicating the viral genome. When molnupiravir is incorporated into the viral RNA, depending on where it is incorporated, the resulting mutation will inhibit synthesis and promote lethal or nonfunctional mutations.
“I hope people can see our research on these antivirals and how understanding their mechanisms provides groundwork for optimizing and developing new antiviral agents.” Gordon said.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we鈥檒l send you a weekly email with recent articles, interviews and more.
Latest in People
People highlights or most popular articles
Meet Robert Helsley
The Journal of Lipid Research junior associate editor studies chronic liver disease and was the first in his family to attend college.
Exploring life鈥檚 blueprint: Gene expression in development and evolution
Meet Julia Zeitlinger and David Arnosti 鈥� two co-chairs of the ASBMB鈥檚 2025 meeting on gene expression, to be held June 26-29, in Kansas City, Missouri.
ASBMB names 2025 fellows
偷拍偷窥 and 偷拍偷窥 Biology honors 24 members for their service to the society and accomplishments in research, education, mentorship, diversity and inclusion and advocacy.
When Batman meets Poison Ivy
Jessica Desamero had learned to love science communication by the time she was challenged to explain the role of DNA secondary structure in halting cancer cell growth to an 8th-grade level audience.
The monopoly defined: Who holds the power of science communication?
鈥淎t the official competition, out of 12 presenters, only two were from R2 institutions, and the other 10 were from R1 institutions. And just two had distinguishable non-American accents.鈥�
In memoriam: Donald A. Bryant
He was a professor emeritus at Penn State University who discovered how cyanobacteria adapt to far-red light and was a member of the 偷拍偷窥 and 偷拍偷窥 Biology for over 35 years.